BioTelemetry Stock News

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host First Quarter 2023 Results Conference Call on Thursday May 9, 2024 at 4:30 p.m. Eastern Time.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias.

HeartBeam (NASDAQ: BEAT ) just reported results for the fourth quarter of 2023. HeartBeam reported earnings per share of -13 cents.

HeartBeam, Inc. (BEAT) Q4 2023 Earnings Call Transcript

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Fourth Quarter and Full Year 2023 Results Conference Call on Wednesday March 20, 2024 at 4:30 p.m. Eastern Time.

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Third Quarter 2023 Results Conference Call on Tuesday November 14, 2023 at 4:30 p.m. Eastern Time.

HeartBeam, Inc. (NASDAQ:BEAT ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Branislav Vajdic - Founder & Chief Executive Officer Robert Eno - President Richard Brou

HeartBeam, Inc. (NASDAQ:BEAT ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Branislav Vajdic - Founder and Chief Executive Officer Rob Eno - President Richard Brounste

Early commercial stage companies burn cash as they scale. A rising interest rate environment is a headwind for companies burning cash.

HeartBeam, Inc. (NASDAQ:BEAT ) Q4 2022 Results Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Branislav Vajdic - Founder and Chief Executive Officer Robert Eno - President Ric

I can only give HeartBeam a hold rating. This cardiac technology firm's stock has risen too much recently. BEAT's 3-month price performance is +349.22%. I think investors should take profit now becaus

Upgrades For UDR Inc (NYSE:UDR), Morgan Stanley upgraded the previous rating of Equal-Weight to Overweight. In the third quarter, UDR showed an EPS of $0.60, compared to $0.51 from the year-ago quarte

Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash. NeuroOne Medical Techn

HeartBeam, Inc. (NASDAQ:BEAT ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Branislav Vajdic – Founder and Chief Executive Officer Jon Hunt – Chief Business O

SANTA CLARA, Calif.